FDA Announces Biosimilar, Prescription Drug User Fees
The U.S. Food and Drug Administration on Tuesday continued to release details on next year's user fees, announcing the fees for pharmaceutical and biosimilars applications as well as the much-ballyhooed, preapplication...To view the full article, register now.
Already a subscriber? Click here to view full article